Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. - Wikidata - awgldk - TriplyDB

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

http://www.wikidata.org/entity/Q34162571

about

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.Fostamatinib Disodium.Proteomic and genetic approaches identify Syk as an AML target.SYK regulates mTOR signaling in AML.STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice Getting Syk: spleen tyrosine kinase as a therapeutic target.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.Progress towards the development of SH2 domain inhibitors.Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies The SYK tyrosine kinase: a crucial player in diverse biological functions.Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells.B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma.TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.New targets of therapy in T-cell lymphomas.Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.The Syk kinase as a therapeutic target in leukemia and lymphoma.Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.B-cell receptor pathobiology and targeting in NHL.More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.B cell receptor signaling in chronic lymphocytic leukemia.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Overview of the Use of Murine Models in Leukemia and Lymphoma Research.A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.

P2860

Q24599100-3459AF7E-2BD5-4D70-8055-4580FBFC43F3 Q26859114-13457A6C-9AE0-4F0E-B109-6D78397D8934 Q28742585-524286C1-EF51-4A09-8369-C3EDFE6CBAE5 Q33392880-8A586498-EE54-4C2D-8480-F71AB50DC57E Q33405080-0C48DF20-FCA0-48B8-804E-09AC2BB55AC9 Q33577098-3A1F65D1-439F-4981-9DE1-52861F60935A Q33641643-48E9AA52-6C00-4EC4-A61F-A14BF3DDD37B Q33733773-0BD57335-3B1D-4721-B7BB-E7C4809E3F80 Q33987268-64F05876-DBAE-4699-BBBE-8903204B151E Q33993750-63FB88D0-141B-4960-A999-0334C3EA5C81 Q34081881-D5339D35-42CE-404B-A807-21A53AE7AC5D Q34297938-6FDCB101-A60B-43F9-B081-40774D59855B Q34581878-B7696388-D6D0-4B0E-AAAE-0E1528406BED Q34625171-A2BD84A1-B960-4310-A86B-F4980AFDC5A9 Q34700655-CF92D1E9-A207-42FC-83F1-40CB914D9B36 Q35423739-E88B0635-9CA1-4FD4-9A8F-F8FD56902219 Q35797583-D228543E-1196-455F-A10C-CB2D2F57197B Q36462375-481163AD-B11F-4E73-A953-11D7103849E3 Q36602853-65D3DB67-5A11-4495-AA75-94C4A4A9C799 Q36662082-B1ADCA3B-5461-4887-8CD3-2749FC26D743 Q36760430-57A341A4-A552-4EF1-9120-45F59BDBC984 Q37025183-FF18F06B-A72A-4CC8-BE5D-CC1418F9E2D9 Q37028635-8ADAD2D1-E13D-45A6-AB4E-78F94B81026A Q37234623-A0BE6D75-5379-459D-859D-C918EAFB8326 Q37280599-0CDA3F17-5C25-4A79-8AA9-42889C2B801D Q37460331-D9B375B0-6BC4-46FC-BAA2-34BD043C9EEF Q37701472-60B453BF-578A-4E9A-88C6-D84762C06C80 Q37788239-BDB4AE9B-30AB-4BD0-B7B7-CE76BE592860 Q37857853-76DB6C80-9212-457B-A37E-A557517FDC24 Q37959298-3474727C-DC6D-45B4-9222-F42FB4E77CA6 Q38032206-1D14582B-9B93-405F-AD58-BD5EA5D0A458 Q38066944-9B976A8D-E592-4C20-8515-9846C9CC0E11 Q38069567-5075765F-6EA8-454D-A3D0-C149B8079041 Q38124120-BEB5205A-6B79-42AF-AE19-5273DCC8CE90 Q38127513-D5A646C3-E03B-4E98-A94C-ABA093C84CF1 Q38150876-7F31F3EA-4748-431C-9741-E9AC70BDC8D9 Q38189089-2762280E-E287-4528-875C-42CEBDEDEDD1 Q38294626-CC1C4914-928A-4C57-83B5-A65D414AF560 Q38749909-317B46C1-5694-48B4-AFBF-1B19F75F4961 Q39122968-6C27CA52-3847-4A6B-A25F-9D2F54FCAB1A

P2860

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

http://www.wikidata.org/entity/Q34162571

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@ast

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@en

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@nl

type

label

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@ast

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@en

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@nl

prefLabel

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@ast

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@en

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@nl

P1433

Q34162571-9EB40E08-3821-4845-BAEC-B39B836EE098

P1476

Q34162571-6C952124-BAEC-4DD0-9BF6-104E07AB73F9

P2093

Q34162571-2E9A2AA1-950C-4E40-A3B6-284D794AF21A

Q34162571-2E9E1C7C-6F96-49B7-9473-ED2E5688EB08

Q34162571-4F3113B8-3D93-43D3-93B5-F7EC3DE57B19

Q34162571-6709DB81-FC9F-48E5-9880-E4BCBA1C2D6A

Q34162571-730FD0CA-E7E6-42F3-A671-2C07D243BD07

Q34162571-8D2C604D-C37D-4513-BB0C-BDEE191A0F26

Q34162571-9CD98A3E-E29D-445E-9CCA-9A1649F95529

Q34162571-F93D74B1-5893-464C-A621-25138F1F8126

P2860

Q34162571-01304160-4A33-4C7B-9530-2A61098C9AF5

Q34162571-0F8965CA-76ED-41EA-9328-E6BF7FFDB745

Q34162571-1826C2C0-C01C-4420-854E-0A964DE67AB9

Q34162571-1D046429-1E14-4F73-8AC1-4A2856FD9881

Q34162571-1D943D8B-17A2-4CDB-9033-F356A616A8BA

Q34162571-224B41EF-264E-4A2B-8BBE-D9F235D722C0

Q34162571-2DC90DE2-FA52-4C31-B61F-9AA7C9C4B6B0

Q34162571-3067D4D1-3ED8-4C93-9C68-DDA45353B9ED

Q34162571-3994D3E2-E842-4FA0-AC45-024D4C34D8CE

Q34162571-3B1B4413-63A8-4E05-827F-64890CC4D2A6

P304

Q34162571-CEAD1E4D-4408-4808-853E-6DF181F71ACA

P31

Q34162571-9A32C226-72D1-4FFE-9FDF-4A66F48D231D

P356

Q34162571-4BF5190A-141E-4290-BDAF-0CA2EBA2D6DF

P407

Q34162571-4BD18FF2-31A6-4639-B7C9-C62DFEF65E24

P433

Q34162571-4B32BC90-665F-41FC-81A2-0FA2CB9A85BF

P478

Q34162571-23A2D6CD-F6FD-4F3C-A2A3-72C59D499D4A

P577

Q34162571-36C772EC-A0AA-40C8-A52B-D186A38641A7

P5875

Q34162571-55E515FE-F164-4CB9-8F74-7CB1F673EE64

P698

Q34162571-D23E65E1-131E-462E-A716-F8ED70402F94

P932

Q34162571-390D0C1D-6A1B-4F5F-8128-778B785FA63C

P356

BLOOD-2008-05-158618

P1433

P1476

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

@en

P2093

Brian C Turner

http://www.w3.org/2001/XMLSchema#string

Ian R Hardy

http://www.w3.org/2001/XMLSchema#string

Nicolai Lundy

http://www.w3.org/2001/XMLSchema#string

Polly Pine

http://www.w3.org/2001/XMLSchema#string

Raedun L Clarke

http://www.w3.org/2001/XMLSchema#string

Ryan M Young

http://www.w3.org/2001/XMLSchema#string

Terry A Potter

http://www.w3.org/2001/XMLSchema#string

Yosef Refaeli

http://www.w3.org/2001/XMLSchema#string

P2860

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

Cre-lox-regulated conditional RNA interference from transgenes

Interference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igbeta cytoplasmic tail

Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.

ZAP-70 in B cell malignancies

Syk tyrosine kinase required for mouse viability and B-cell development

Rational siRNA design for RNA interference

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas

Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death.

P304

2508-2516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-05-158618

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23448665

http://www.w3.org/2001/XMLSchema#string

P698

18981293

http://www.w3.org/2001/XMLSchema#string

P932

2947310

http://www.w3.org/2001/XMLSchema#string